Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

AVROBIO
300 One Kendall Square, Building 300, Suite 201
Cambridge, MA 02139
http://www.avrobio.com/

AVROBIO, a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients' lives with a single dose. The Company is focused on the development of its gene therapy candidate, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. AVROBIO's lentiviral platform has broad potential for other rare and non-rare genetic diseases.

Key Contact
Name
Geoff MacKay
Title
President & CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
02/01/18 $60,000,000 Series B Aisling Capital
Atlas Venture
Brace Pharma
Clarus Ventures
Cormorant Asset Management
Eventide Asset Management
Morningside Venture
Surveyor Capital
SV Health Investors
undisclosed